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Large population-based studies are needed to establish the magnitude and
duration of the recently suggested association between arterial and venous
thromboembolism. In 1997–98, all inhabitants of Groningen, the Nether-
lands, aged 28–75 years (n = 85 421), were invited to participate in a study
that followed and monitored responding subjects (n = 40 856) for venous
and arterial thromboembolism until 2009. Thromboembolism was verified
with national registries of hospital discharge diagnoses and death certifi-
cates, anticoagulation clinic and medical records. During a median follow-
up of 107 years, 549 participants developed venous thromboembolism and
3283 developed arterial thromboembolism. Annual incidence of arterial
thromboembolism after venous thromboembolism was 203% [95% confi-
dence interval (CI), 148–271], compared to 087% (95% CI, 084–090) in
subjects without venous thromboembolism. The hazard ratio (HR) of arte-
rial thromboembolism after venous thromboembolism was 140 (95% CI,
104–188) after adjustment for age, sex and cardiovascular risk factors.
This risk was highest during the first year after venous thromboembolism
[annual incidence, 300% (95% CI, 164–504); adjusted HR, 201 (95% CI,
119–340)] and after an unprovoked event [annual incidence, 253% (95%
CI, 168–366); adjusted HR, 162 (95% CI, 111–234)]. This study showed
that subjects with venous thromboembolism are at increased risk for arte-
rial thromboembolism, particularly in the first year after venous thrombo-
embolism and after an unprovoked event.
Keywords: arterial thromboembolism, venous thromboembolism.
The concept that arterial and venous thromboembolism are
separate pathophysiological entities has been challenged
(Lowe, 2006). Prandoni et al (2003) were the first to report a
twofold increased risk for the presence of atherosclerotic pla-
ques in patients with unprovoked deep vein thrombosis.
Since then, several studies have examined the relationship
between venous thromboembolism and the risk of subse-
quent arterial thromboembolism and confirmed a relation-
ship between the two diseases. However, their generalizability
is limited due to either a rather small sample-size (Becattini
et al, 2005; Bova et al, 2006), a patient-based cohort (Becat-
tini et al, 2005; Prandoni et al, 2006) or a lack of controls
(Schulman et al, 2006). Also, some studies were limited by
possible misclassification of outcome events due to the retro-
spective way in which the cardiovascular events were
obtained (Spencer et al, 2008; Klok et al, 2009). In a recent
meta-analysis (Becattini et al, 2010) no adjustments for age
could be made. Age is a strong confounder to the risk of
both venous and arterial thromboembolism, hence, based on
this meta-analysis, we can not firmly conclude that the
higher incidence of arterial thromboembolism after venous
thromboembolism is truly related to previous venous throm-
botic disease, as it can also merely be a result of ageing. The
limitations of the abovementioned studies preclude an accu-
rate estimation of the absolute incidences of cardiovascular
arterial disease in patients with venous thromboembolism.
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This information, however, is important for the clinical man-
agement of these patients. A large population-based study
was performed, in which the limitations discussed above
were taken into account (Sorensen et al, 2007). This study
found a two- to three-fold increased risk of arterial thrombo-
embolism after first venous thromboembolism, predomi-
nantly in the first year following initial venous
thromboembolism (Sorensen et al, 2007). However, large
population-based studies on this issue are still needed to fur-
ther establish the magnitude and duration of the association
between arterial and venous thrombosis.
The Prevention of REnal and Vascular ENd stage Disease
(PREVEND) Study (Hillege et al, 2001) offered us the
opportunity to investigate the incidence of arterial and
venous thrombotic disease in a large population-based
cohort. We intended to use this study to advance our under-
standing of both arterial and venous thrombotic disease and
provide further insight into the clinical course of patients
with venous thromboembolism. Our aims were to establish
whether venous thromboembolism is a risk factor for subse-
quent arterial thromboembolism, and to determine the abso-
lute risk of arterial thromboembolism after venous
thromboembolism, in a prospectively followed population-
based cohort of more than 40 000 subjects.
Methods
Study population
This study was conducted on participants in the PREVEND
Study, which was designed to prospectively investigate the
natural course of albuminuria and its relationship with renal
and cardiovascular disease in a large cohort drawn from the
general population. Within the PREVEND Study design,
arterial thromboembolic events were collected prospectively.
Details of this study have been published previously (Hillege
et al, 2001) and can be found at http://www.prevend.org. In
1997–98, all inhabitants of the city of Groningen, the Nether-
lands, aged 28–75 years (n = 85 421) were sent a postal
questionnaire and a vial to collect an early morning urine
sample. A total of 40 856 subjects (478%) responded. Their
observation time started at study entry and ended at time of
arterial thromboembolism, moving out of the city, death or
end of study (January 2009).
All participants gave written informed consent. The PRE-
VEND Study was approved by the local medical ethics com-
mittee and was conducted in accordance with the guidelines
of the Declaration of Helsinki.
Definition of thrombotic events
To identify subjects with arterial and venous thromboembo-
lism, the databases of the national registry of hospital discharge
diagnoses (Prismant, Utrecht, the Netherlands) and death cer-
tificates (Central Bureau of Statistics, The Hague/Heerlen, the
Netherlands) were linked yearly to the PREVEND database. In
addition, the database of the regional anticoagulation clinic,
which monitors the anticoagulant therapy of all inhabitants of
the city of Groningen, was searched for venous events. When
available, data on subjects with venous thromboembolism
according to any of the abovementioned databases was con-
firmed by patients’ medical records (n = 522). Arterial throm-
boembolism was predefined as acute myocardial infarction
[International Classification of Diseases (ICD)-code 410],
acute and subacute ischaemic heart disease (411), occlusion or
stenosis of the precerebral (433) or cerebral arteries (434), cor-
onary artery bypass grafting (CABG) or percutaneous translu-
minal coronary angioplasty (PTCA), and other vascular
interventions, such as percutaneous transluminal angioplasty
or bypass grafting of aorta and peripheral vessels (Oterdoom
et al, 2009).
Deep vein thrombosis had to be confirmed by compres-
sion ultrasound, and pulmonary embolism by ventilation/
perfusion lung scanning, spiral computed tomography, or at
autopsy. When deep vein thrombosis and pulmonary embo-
lism were diagnosed simultaneously, this was classified as
pulmonary embolism. Only deep vein thrombosis and
pulmonary embolism were considered in the present study,
other types of venous thrombosis were not included.
Venous thromboembolism was classified as being provoked
when it had occurred at or within 3 months after exposure
to an exogenous risk factor including surgery, trauma,
immobilization for more than 7 d, pregnancy, puerpe-
rium, the use of oral contraceptives or hormonal replacement
therapy, or malignancy. Venous thromboembolism was
classified as unprovoked when no such exogenous risk factor
was present.
Measurements
The questionnaire provided information about the presence
of established risk factors for cardiovascular disease. Sub-
jects were classified as being diabetic when they gave a
positive answer when questioned if they had been diag-
nosed with diabetes by a physician, regardless of the type
of anti-diabetic treatment. Subjects were considered hyper-
tensive or dyslipidaemic when they positively answered the
question regarding whether high blood pressure or high
cholesterol, respectively, had ever been measured. Those
who reported smoking or having smoked cigarettes during
the previous 5 years were regarded as smokers. A history
of myocardial infarction or stroke was considered present
if subjects positively answered the question regarding
whether they ever suffered from myocardial infarction or
ischaemic stroke.
Morning urinary albumin concentration was established
by a commercial immunoturbidimetry assay with sensitivity
of 23 mg/l and inter- and intra-assay coefficients of varia-
tion of 22% and 26% respectively (BN II, Dade Behring
Diagnostica, Marburg, Germany) (Hillege et al, 2001, 2002).
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First morning urine was used for analysis. Albuminuria was
considered elevated at a concentration of 20 mg/l or more
(Bangstad et al, 1991).
Statistical analysis
We estimated the absolute risk of arterial thromboembolism
in subjects with and without venous thromboembolism to
assess whether venous thromboembolism is a risk factor for
arterial thromboembolism. The absolute risk was expressed
as an annual incidence and was calculated by dividing the
number of arterial events by the time at risk. The 95% confi-
dence intervals (CIs) around the annual incidences were
assessed with the Poisson distribution assumption. A time-
varying exposure Cox proportional hazard model was used
to estimate whether venous thromboembolism was a risk fac-
tor for arterial thromboembolism. With this model, we
accounted for differences in the onset of venous thromboem-
bolism, i.e. subjects were allocated to the non-venous throm-
boembolic group and added follow-up time to this group as
long as they did not develop venous thromboembolism. At
the time that subjects developed venous thromboembolism
they switched to the venous thromboembolic group and
started adding follow-up time to this group. Adjustments
were made for age, sex, hypertension, dyslipidaemia, diabetes
mellitus, smoking status, elevated albuminuria and history of
arterial thromboembolism. Based on clinically relevant differ-
ences, preplanned sensitivity analyses were performed for the
subgroups of venous thromboembolism (i.e. deep vein
thrombosis versus pulmonary embolism and unprovoked
versus provoked venous thromboembolism). Furthermore, a
priori planned subanalyses were performed for the first year
of follow-up after venous thromboembolism versus the
rest of follow-up, to investigate the persistence of venous
thromboembolism as a risk factor through time.
As hospitalization bias can cause misclassification of out-
come events due to differences in monitoring subjects with
or without venous thromboembolism, an additional sensitiv-
ity analysis was performed in which only the arterial throm-
boembolic outcome events myocardial infarction, ischaemic
stroke or death due to arterial thromboembolism were
regarded. Categorical data are presented as counts and per-
centages, continuous variables as medians with interquartile
ranges (IQR). Statistical significance was considered as
2-tailed P < 005. Statistical analyses were performed using
PASW version 180 (IBM SPSS, Chicago, IL, USA) and SAS
version 92 (SAS Institute, Inc, Cary, NC, USA).
Results
Study population
Baseline characteristics are shown in Table I. Out of 40 856
participants 46% was male. Median follow-up time was 107
(IQR, 88–110) years. Median age at enrolment was 60
(IQR, 48–68) and 48 (IQR, 39–60) years for subjects with
and without venous thromboembolism respectively. Venous
thromboembolism occurred in 549 subjects at a median age
of 64 years (IQR, 53–73). In 256 subjects the venous event
was secondary to an external risk factor, 249 events were
unprovoked. In 44 events the presence or absence of an
external risk factor could not be assessed from medical
records. Arterial thromboembolism occurred in 3283 subjects
(ICD-code 410, 33%; 411, 29%; 433, 5%; 434, 14%; CABG,
8%; PTCA, 5%; other, 6%). Forty-five subjects with venous
thromboembolism subsequently developed arterial thrombo-
embolism at a median age of 72 years (IQR, 65–78). In the
group without venous thromboembolism, 3238 subjects
developed arterial thromboembolism at a median age of
69 years (IQR, 60–74). The type of thromboembolic event is
shown in Table II. Type of arterial thromboembolic event
(ICD-9 coding) was equally distributed between the subjects
with and without venous thromboembolism (data no
shown).





Total 549 (100) 40 307 (100)
Male 260 (47) 18 365 (46)
Age at enrolment,
years
60 (48–68) 48 (39–60)
Cardiovascular risk factors
Hypertension 197 (36) 11 642 (29)
Dyslipidaemia 83 (15) 5566 (14)
Diabetes mellitus 18 (3) 1033 (3)
Current smoker 202 (37) 16 946 (42)
Microalbuminuria
( 20 mg/l)
60 (11) 3140 (8)
History of arterial
thromboembolism
30 (6) 1749 (4)
Continuous variables are presented as median (IQR), categorical
variables as number (%).
Table II. Type of thrombotic event
Number (%)
Venous thromboembolisn 549 (100)
Deep vein thrombosis 313 (57)
Pulmonary embolism 175 (32)
Deep vein thrombosis and pulmonary embolism 61 (11)
Arterial thromboembolism 3283 (100)
Acute myocardial infarction 1079 (33)
Acute and subacute ischaemic heart disease 966 (29)
Occlusion or stenosis of the precerebral arteries 173 (5)
Occlusion or stenosis of the cerebral arteries 448 (14)
Coronary artery bypass grafting 258 (8)
Percutaneous transluminal coronary angioplasty 149 (5)
Other vascular interventions 210 (6)
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In the patients with venous thromboembolism, the med-
ian treatment time with anticoagulation was 6 (IQR, 3–10)
months. Of the 45 subjects who developed arterial thrombo-
embolism after venous thromboembolism, 17 subjects were
still on anticoagulant therapy. One subject had stopped tak-
ing anticoagulant therapy <1 month before developing arte-
rial thromboembolism, in all others the interval between
cessation of anticoagulant and arterial thromboembolism was
longer than 1 month.
In 9547 out of 40 856 participants, follow-up ended pre-
maturely at time of non-arterial and non-venous vascular
event (n = 220, 05%), non-cardiovascular death (n = 2222,
54%) or moving out of the city (n = 7105, 174%).
Risk of arterial thromboembolism after venous
thromboembolism
Figure 1 shows the risk of arterial thromboembolism after
venous thromboembolism. The annual incidence of arterial
thromboembolism after prior venous thromboembolism was
203% (95% CI, 148–271), compared to 087% (95% CI,
084–090) in subjects without venous thromboembolism.
The crude hazard ratio (HR) of subsequent arterial thrombo-
embolism was 224 (95% CI, 167–300, P < 0001) in sub-
jects with venous thromboembolism, compared to subjects
without. After adjustment for age, sex, cardiovascular risk
factors and previous arterial thromboembolism, the HR was
140 (95% CI, 104–188, P = 003). Within this model, age
was a strong confounder as adjustment for age only resulted
in a HR of 143 (95% CI, 106–192, P = 002).
Our preplanned subgroup analysis of venous thromboem-
bolism indicated that the differences between subjects
with deep vein thrombosis and subjects with pulmonary
embolism were minimal. With an adjusted HR of 162 (95%
CI, 111–234, P = 001), subjects with unprovoked venous
thromboembolism were seemingly at higher risk of arterial
thromboembolism than subjects with provoked venous
thromboembolism [adjusted HR of 122 (95% CI, 071–211,
P = 047)].
Risk of arterial thromboembolism was highest within the
first year after venous thromboembolism with an annual
incidence of 300% (95% CI, 164–504) and an adjusted HR
of 201 (95% CI, 119–340, P = 001). This higher risk was
predominantly found in subjects with deep vein or unpro-
voked thrombosis [adjusted HR, 268 (95% CI, 144–499,
P = 0002) and 291 (95% CI, 157–542, P < 0001) respec-
tively]. After 1 year of follow-up, the adjusted HR of arterial
thromboembolism after venous thromboembolism decreased
to 123 (95% CI, 086–175, P = 026).
To explore the influence of misclassification due to hospi-
talization bias, a subanalysis was performed in which cardio-
vascular outcome was limited to myocardial infarction,
Fig 1. Risk of arterial thromboembolism after venous thromboembolism. 95% CI, 95% confidence interval.
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ischaemic stroke and cardiovascular death. Out of the 3283
subjects that developed an arterial event during follow-up,
1873 subjects developed myocardial infarction, ischaemic
stroke or cardiovascular death. Twenty-seven of these arterial
thromboembolic events developed subsequent to venous
thromboembolism, while 1846 subjects did not suffer from
prior venous thromboembolism. The annual incidence of
myocardial infarction, ischaemic stroke or cardiovascular
death in subjects with previous venous thromboembolism
was 122% (95% CI, 081–177), compared to 049% (95%
CI, 047–052) in subjects without previous venous thrombo-
embolism. The overall crude HR of myocardial infarction, is-
chaemic stroke or cardiovascular death was 234 (95% CI,
160–342, P < 0001) in subjects with venous thromboembo-
lism, compared to subjects without. Multivariate analysis
showed an overall adjusted HR of 142 (95% CI, 097–208,
P = 007). Within the first year, this adjusted HR was 193
(95% CI, 096–387, P = 006). After 1 year of follow-up, the
adjusted HR of myocardial infarction, ischaemic stroke or
cardiovascular death after venous thromboembolism
decreased to 128 (95% CI, 081–201, P = 029).
Discussion
This large population-based cohort study showed that sub-
jects with previous venous thromboembolism are at increased
risk to develop arterial thromboembolism. Although age was
a strong confounder to this risk, the risk was still 14-fold
increased after adjustment for age, sex, cardiovascular risk
factors and history of arterial thromboembolism.
The overall absolute risk for arterial thromboembolism in
subjects with venous thromboembolism was as high as 20%
per year and even 30% during the first year after a diagnosis
of venous thromboembolism. These values approach the
absolute risk of recurrent venous thromboembolism (Heit
et al, 2000; Christiansen et al, 2005). These data indicate that
clinicians should be aware of the possibility of arterial
thromboembolism, as well as recurrent venous thromboem-
bolism. It also implicates that the treatment of patients with
venous thromboembolism may have to be reconsidered. A
meta-analysis concluded that acetyl salicylic acid, known for
its preventive effect for cardiovascular disease, is also effective
in preventing venous thrombosis (Karthikeyan et al, 2009).
As yet, however, there is insufficient evidence to advise a
combination of vitamin K antagonists and antiplatelet ther-
apy in order to prevent both recurrence and arterial throm-
boembolism after a first venous thromboembolism. Two
ongoing studies (Warfasa, agnellig@unipg.it and Aspire,
aspire@ctc.usyd) address this issue. Another option might be
to prescribe statins to patients with venous thromboembo-
lism. In addition to their lipid-lowering and cardioprotective
capacity, these drugs also appear to decrease the risk of
venous thromboembolism (Agarwal et al, 2010).
Our results showed that the risk of arterial thromboem-
bolism is highest during the first year after venous throm-
boembolism, especially in patients with an unprovoked
event. This finding is in accordance with other studies
(Sorensen et al, 2007; Klok et al, 2009). The early occur-
rence of cardiovascular events is difficult to understand, as
patients with venous thromboembolism usually receive anti-
coagulant therapy in the first 3–6 months following their
event and anticoagulant therapy is known to prevent car-
diovascular events (Anand & Yusuf, 1999). In the early
1960s it was observed that an increased risk of cardiovascu-
lar events occurred after cessation of oral anticoagulant
therapy (Dinon & Vander Veer, 1960). This high risk was
assigned to a rebound effect on coagulant factors (Grip
et al, 1991; Genewein et al, 1996; Ascani et al, 1999). This
notion, however, was not corroborated by others (Van
Cleve, 1965; Sharland, 1966; Tardy et al, 1997) and there-
fore remains controversial. In our cohort, only one subject
developed arterial thromboembolism within a month after
cessation of anticoagulant therapy, indicating that the pres-
ence of a rebound effect is unlikely.
Given these considerations, we hypothesize that the high
risk of arterial thromboembolism within the first year after
venous thromboembolism suggests that a joint mechanism
relates the two diseases. The presence of underlying pathol-
ogy affecting the venous system might also affect the arterial
system. The high risk of arterial thromboembolism in sub-
jects with an unprovoked venous event compared to those
with a provoked event supports this idea, as does our finding
that the relationship between arterial and venous thrombo-
embolism persists after adjustment for self-reported cardio-
vascular risk factors. Which underlying pathology could
relate the two diseases cannot be concluded from our study.
An explanation could be bodyweight. Obesity is related to a
higher risk of arterial (Hubert et al, 1983; Yusuf et al, 2004)
and venous thromboembolism (Tsai et al, 2002; Stein et al,
2005). This might partly explain the relationship between
arterial and venous thromboembolism through endothelial
damage and/or the related changes in the levels of procoagu-
lant proteins (Arcaro et al, 1999; Rosito et al, 2004). How-
ever, in a subset of patients for whom data on body mass
index was available, adjustment for body mass index did not
affect the risk of arterial thromboembolism after venous
thromboembolism (data not shown).
Our study has both strengths and limitations. The
strengths include the large population-based cohort, long fol-
low-up time, prospectively collected data on arterial events,
estimation of absolute risks and the adjustments made for
age and sex in all analyses. A limitation of our study is that
the data on cardiovascular risk factors were collected using
self-reported histories at baseline. Data on the development
of arterial cardiovascular risk factors during follow-up is not
available. Furthermore, data regarding anticoagulant therapy
were only available for the subjects who developed venous
thromboembolism during follow-up. Hence, the use of anti-
coagulants was not included in our multivariate analyses and
so we were not able to address the recent finding that antico-
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agulation therapy might accelerate arterial calcification
(Rennenberg et al, 2010). The incidence of venous thrombo-
embolism in our cohort may be underestimated as venous
thromboembolism cases were retrospectively identified.
Nonetheless, as compared with other prospective studies, our
annual incidence of 015% is rather high as our cohort was
confined to individuals younger then 75 years (Naess et al,
2007). Lastly, the higher risk of arterial thromboembolism
after venous thromboembolism may be spurious due to mis-
classification of arterial thromboembolism caused by hospi-
talization bias. Nonetheless, our subanalysis with outcome
restricted to myocardial infarction, ischaemic stroke and
death due to arterial thrombosis, confirmed the primary
analysis. Therefore, we conclude that misclassification was
only marginal, if present. As shown in Fig 1, subgroup analy-
ses were limited due to small numbers of arterial events,
resulting in wider confidence intervals. For the same reason,
we refrained from assessing differences in pulmonary embo-
lism versus deep vein thrombosis and unprovoked versus pro-
voked venous thromboembolism in this sensitivity analysis
with restricted arterial outcome.
We conclude from this large cohort study that subjects
with venous thromboembolism are at an increased risk to
develop arterial thromboembolism. This risk is especially
high in the first year after venous thromboembolism and
after an unprovoked event. The risk persists after adjust-
ment for age, sex, cardiovascular risk factors and previous
arterial thromboembolism. Our findings implicate that
the care for patients with venous thromboembolism should
not only focus on the prevention of recurrent venous
thromboembolism but also on the prevention of arterial
thromboembolism.
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